View Older Stories View More Recent Stories
-
RBC Capital on Ultragenyx Pharma (RARE): 'We Believe RARE Has A Drug For Osteogenesis Imperfecta'
-
RBC Capital: 'Our Top 3 Canadian Technology Ideas for 2025'
-
Mosaic (MOS) PT Lowered to $27 at RBC Capital; 'Potential Upside if Phosphate Prices Stay Up'
-
APA Corporation Announces Expiration and Final Results of Private Exchange Offers, Tender Offers, and Consent Solicitations and Waiver of Financing Condition
-
RBC Capital on ICON plc (ICLR): 'We Consider ICLR To Be One Of Our Top Ideas For The Upcoming Year'
-
Waystar Holding (WAY) PT Raised to $42 at RBC Capital
-
Flowers Foods (FLO) To Acquire Simple Mills
-
FLOWERS FOODS, INC. TO ACQUIRE SIMPLE MILLS
-
Solaris Expands Leadership Team
-
Shell warns of weaker fourth quarter LNG, oil trading
-
RBC Capital Downgrades OptimizeRX (OPRX) to Sector Perform
-
RBC Capital Upgrades Phreesia Inc. (PHR) to Outperform
-
Kimbell Royalty Partners LP (KRP) Announces Pricing of Upsized Public Offering of Common Units
-
Kimbell Royalty Partners, LP Announces Pricing of Upsized Public Offering of Common Units
-
EnCap Flatrock Midstream Completes Two Transactions with Plains All American
-
Exxon signals weaker performance across the board to hurt Q4 profits
-
Kimbell Royalty Partners LP (KRP) Announces Public Offering of Common Units
-
Kimbell Royalty Partners, LP Announces Public Offering of Common Units
-
Fisher Investments Finalizes Strategic Partnership with Advent and ADIA with Completion of Minority Common Stock Investment
-
bluebird bio (BLUE) PT Slashed to $8 at RBC Capital, Citing Three Severe Adverse Events
-
Vertex (VRTX) PT Raised to $401 at RBC Capital; 'We Would Look for a More Compelling Entry Point'
-
Regeneron Pharma (REGN) PT Lowered to $1,184 at RBC Capital
-
Gilead Sciences (GILD) PT Lowered to $83 as RBC Capital Highlights Biktarvy's Strong Profile
-
Biogen (BIIB) PT Lowered to $231 as RBC Capital Sees 'Attractive Entry Point for Shares'
-
Apellis Pharmaceuticals (APLS) PT Raised to $26 at RBC Capital
-
Amgen (AMGN) PT Lowered to $324 at RBC Capital Despite Improved Growth Visibility
-
RBC Capital Analyzes Key Auto Players in Light of D3 Dealer Data
-
RBC Capital Reiterates Outperform on Verisk Analytics (VRSK), Expecting Guidance Inline with Midterm Outlook
-
RBC Capital Reiterates Outperform Rating on Constellation Brands (STZ); 'Expecting Shares to Remain Rangebound'
-
Agree Realty (ADC) PT Lowered to $79 at RBC Capital Following Estimates Reduction
-
RBC Capital Reiterates Outperform Rating on Well Health Technologies Corp. (WELL:CN) (WLYYF), 'a preferred stock pick in 2025'
-
RBC Capital Starts ICON plc (ICLR) at Outperform
-
RBC Capital Upgrades Carvana (CVNA) to Outperform
-
F&G Annuities & Life Prices Junior Subordinated Notes Offering
-
RBC Capital Names Top Ideas in '2025 Outlook Refresh' Note
-
Primo Brands Corp. (PRMB) PT Raised to $38 at RBC Capital
-
RBC Capital Reiterates Outperform Rating on CGI Group Inc (GIB/A:CN) (GIB) on Organic Growth Potential
-
Talen Energy Supply Announces Commencement of Consent Solicitation for Its 8.625% Senior Secured Notes Due 2030
-
3 non-consensus software stocks to buy for 2025: RBC
-
RBC Capital Assumes EQB Inc (EQB:CN) (EQGPF) at Outperform
-
RBC Capital Downgrades T-Mobile US, (TMUS) to Sector Perform
-
RBC Capital Upgrades AT&T (T) to Outperform
-
RBC Capital Upgrades Republic Services (RSG) to Outperform
-
RBC Capital Downgrades Unilever plc (ULVR:LN) (UL) to Underperform
-
RBC Capital Upgrades Experian Plc. (EXPN:LN) (EXPGY) to Outperform
-
Multi-Industry sector 2025 outlook amid Trump 2.0: RBC
-
RBC names its top picks in the software sector in 2025
-
RBC Capital on Carvana (CVNA), 'Street numbers may be too low'
-
RBC Capital Highlights Favorite Ideas in 2025 Software Outlook Note
-
RBC on CrowdStrike Holdings (CRWD): 'A Compelling Idea in 2025'; PT Raised to $420
